Funding Opportunities

[Med Research]

Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models (U01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-055.html__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgds44x8eH4$ >
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the development of technology tools that will facilitate, accelerate, and/or enhance research using advanced human-derived next generation cancer models (NGCMs), such as organoids, conditionally reprogrammed cells, and others. The studies proposed under this FOA must focus entirely on the next generation cancer models developed under the auspices of an international consortium with NCI participation, Human Cancer Models Initiative<https://urldefense.com/v3/__https://hcmi-searchable-catalog.nci.nih.gov/__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgdsh7JGvrA$ >. "Technology tools" to be developed under this FOA may include new and/or optimized laboratory methods, reagents/reference materials, agents for NGCMs perturbation or screening read-outs, and/or software/bioinformatics tools for data processing and/or facilitated/enhanced interpretations. (The development of new hardware/equipment will not be supported). The proposed technology tools are expected to a) facilitate the utilization of the cancer models, e.g., in terms of increasing robustness, rigor, and/or reproducibility of results, b) enable advanced interpretations of experiments in which these model are used, c) design and test genomic editing/manipulating reagents for all cancer and NGCM types, and d) develop robust approaches to method standardization, quality assurance/control, etc., that could serve as routine workflows/best practices for use in a wide range of laboratories. The collective outcomes of projects under this FOA should facilitate the adoption of NGCMs by the research community and expedite sharing and validating of NGCMs-derived results. The new tools and broader use of NCGMs are expected to contribute to the progress in such areas as the identification of novel therapeutic targets, mechanisms of resistance, development of diagnostic and/or predictive biomarkers, and other aspects relevant to precision oncology.
Due August 30, 2019. Med-RA deadline to receive draft documents: August 19, 2019.

BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-19-001.html__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgdsRpUrMsI$ >
This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new and novel noninvasive human brain imaging technologies and methods that will lead to transformative advances in our understanding of the human brain. The FOA solicits unusually bold and potentially transformative approaches and supports small-scale, proof-of-concept development based on exceptionally innovative, original and/or unconventional concepts.
Due September 3, 2019. Med-RA deadline to receive draft documents: August 19, 2019.

Computational Methods for Integrating Tissue and Single Cell Genomic Data from the Brain (R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-300.html__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgds5wsCGSI$ >
The purpose of this Funding Opportunity Announcement is to support the development or application of advanced computational and statistical tools to integrate brain tissue and single-cell genomic data in order to advance our understanding of the cell type-specific gene regulatory networks and biological pathways involved in the pathogenesis and pathophysiology of major mental disorders.
Due September 3, 2019. Med-RA deadline to receive draft documents: August 19, 2019.

BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-eb-19-002.html__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgds8IBriM8$ >
This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support full development of entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. The FOA seeks innovative applications that are ready for full-scale development of breakthrough technologies with the intention of delivering working tools.
Due September 3, 2019; September 3, 2020; and September 3, 2021. Med-RA deadline to receive draft documents for 2019 deadline: August 19, 2019.

BRAIN Initiative: Non-Invasive Neuromodulation - New Tools and Techniques for Spatiotemporal Precision (R01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-310.html__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgdscDPCWrY$ >
This Funding Opportunity Announcement (FOA) solicits grant applications in two related but distinct areas. The first area is in the development and testing of novel tools and methods of neuromodulation that go beyond the existing forms of neural stimulation. The second distinct area that this FOA seeks to encourage is the optimization of existing stimulation methods.
Due September 3, 2019 and February 14, 2020. Med-RA deadline to receive draft documents for September deadline: August 19, 2019.

Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-022.html__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgdslXQU3wI$ >
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).
Due October 8, 2019; July 20, 2020; and March 8, 2021. Med-RA deadline to receive draft documents for October deadline: September 24, 2019.

Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed); Center for Tobacco Products<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-021.html__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgdswFnvwMU$ >
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. While other publicly available repositories would be considered, depending on analyses to be conducted, nationally representative analyses will receive priority. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set.
Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).
Due October 8, 2019; August 7, 2020; and March 8, 2021. Med-RA deadline to receive draft documents for October deadline: September 24, 2019.

Molecular Mechanisms of Blood-Brain Barrier Function and Dysfunction in Alzheimer's disease and Alzheimer's related dementias (AD/ADRD) (R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-004.html__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgdsFvsEtO4$ >
The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimer's Disease (AD) and AD-Related Dementias, and how related comorbidities impact the basic molecular mechanisms of BBB health and function.
Due October 9, 2019. Med-RA deadline to receive draft documents: September 25, 2019.

FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-19-306.html__;!5Xm4_O-4tfk!gCOyiT6PIZwDRuaY3W87G6AVQUBAjmdMoef8-1_gAGxLeKHetr7tQ1Mue2QworPphUHE9KHAAgds_MrwnQE$ >
The purpose of the FDA (R13) Scientific Conference Grant Program is to facilitate the provision of federal financial assistance in support of high-quality conferences and scientific meetings designed to research and investigate a topic clearly aligned with the FDA mission. The FDA recognizes the value of supporting high quality conferences and scientific meetings relevant to its mission and to the public health. A conference or scientific meeting is defined as a symposium, seminar, workshop, or any formal meeting, whether conducted face-to-face or virtually to exchange information and explore a defined subject, issue, or area of concern impacting the public's health within the scope of the FDA's mission. Permission to submit a conference grant application does not assure funding or funding at the level requested. FDA will not issue a conference grant award unless it can be issued before the conference start date.
Due October 11, 2019; April 13, 2020; October 13, 2020; April 12, 2021; October 12, 2021; April 12, 2022; and October 11, 2022.
Note: Prior approval (advance permission to apply) in the form of a Letter of Intent is required before submission of an application for conference support. Advance permission to submit an application must be requested early in the process and must be submitted no later than 8 weeks before the selected application due date. Letter(s) of Intent received after 8 weeks prior to the application submission date will not be accepted. Med-RA deadline to receive draft documents for 2019 Letter of Intent deadline: August 5, 2019.

To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20190729/a25653b5/attachment.html>